Program 1 Clinical stage
Acute Ischemic Stroke (AIS)
A Phase Ib/IIa trial (clinical Proof-of-Concept) to assess the safety and neuroprotective effect of ApTOLL in patients is currently in progress (enrollment of Phase Ib already completed).
Program 2 clinical stage
A Phase Ib trial to assess the safety and protective effect of ApTOLL in hospitalized patients susceptible to develop an uncontrolled inflammatory process.
Program 3 Preclinical stage
Intracerebral Hemorrhage (ICH)
Preclinical studies are being conducted to confirm ApTOLL’s neuroprotective effect in intracerebral hemorrhage. Experimental models of intracerebral hemorrhage are being used to evaluate the impact of ApTOLL treatment on short- and long-term disease progression.
Program 4 Preclinical stage
Myocardial Infarction (MI)
Preclinical studies confirmed ApTOLL’s anti-inflammatory and cardioprotective effect in acute myocardial infarction. These studies evaluated the impact of ApTOLL administration in infarct volume and cardiac remodeling using ischemia-reperfusion models in rodents and swine.
Program 5 Preclinical stage
Multiple Sclerosis (MS)
Preclinical studies are being conducted to determine ApTOLL’s neuroprotective and regenerative effect in multiple sclerosis. These studies are evaluating the immunomodulatory and remyelinating effect of ApTOLL in different experimental models of multiple sclerosis.